While there are still no COVID-19 treatments approved by the Food and Drug Administration, scientists have found some success in hastening the recovery time of severe patients by using remdesivir.
HHS has secured more than 500,000 treatment courses of the drug for US hospitals through September, the agency said on Monday. In a USA government-led study, remdesivir shortened recovery time by 31 percent - 11 days on average versus 15 days for those given just usual care.
Gilead has entered into an agreement with the U.S. Department of Health and Human Services (HHS) whereby the department and states will manage allocation to hospitals until September end.
Gilead Sciences Inc said it is pricing remdesivir at $390 per vial for people covered by government healthcare in the USA and other developed countries. We also balanced that with our longer-term responsibilities: "to continue with our ongoing work on remdesivir, to maintain our long-term research in antivirals and to invest in scientific innovation that might help generations to come".More news: Governor closes bars, rolls back reopening
The per-vial price outside of private insurance will be $390, Gilead added.
Other advocates, including consumer-rights group Public Citizen, have said the drug should just cost $1 a day based on calculations that it could be manufactured at scale by generic drugmakers for this amount.
The price tag is below the $5,080 per course recommendation by US drug pricing research group, the Institute for Clinical and Economic Review (ICER), last week. It experienced not enhanced survival in accordance to preliminary final results right after two months of followup final results right after 4 months are anticipated quickly.
But recent news that a cheap steroid called dexamethasone - a common $50 steroid - improves survival means remdesivir should be priced between $2,520 and $2,800, the group said.More news: IPhone 12 to Come Without Power Adapter, EarPods in Box: Kuo
In an interview with The Wall Street Journal, O'Day said the US was the only developed country to get two prices. "Given the serious nature of the pandemic, I would prefer that the government take over production and distribute the drug for free".
"Remdesivir should be in the public domain" simply because the drug gained at the very least $70 million in general public funding towards its growth, he explained.
"The price puts to rest any notion that drug companies will "do the right thing" because it is a pandemic", Dr Peter Bach, a health policy expert at Memorial Sloan Kettering Cancer Center in NY said in an email.
Gilead Sciences announced Monday that the antiviral drug will cost hospitals about $520 per dose for privately insured patients, the Wall Street Journal reported. It was granted emergency use authorisation by USA regulators in May.More news: Hong Kongers march in silent protest against national security laws